` AVCT (Avacta Group PLC) vs FTSE All Share Index Comparison - Alpha Spread

AVCT
vs
F
FTSE All Share Index

Over the past 12 months, AVCT has significantly outperformed FTSE All Share Index, delivering a return of +50% compared to the FTSE All Share Index's 0% growth.

Stocks Performance
AVCT vs FTSE All Share Index

Loading
AVCT
FTSE All Share Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
AVCT vs FTSE All Share Index

Loading
AVCT
FTSE All Share Index
Difference
www.alphaspread.com

Performance By Year
AVCT vs FTSE All Share Index

Loading
AVCT
FTSE All Share Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Avacta Group PLC vs Peers

FTSE All Share Index
AVCT
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Avacta Group PLC
Glance View

Market Cap
314.2m GBX
Industry
Biotechnology

Avacta Group Plc engages in the provision of Affimer reagents for licensing into third-party research and diagnostic products, and creates new Affimer medicines for development in-house and licensing to large pharmaceutical companies. The company is headquartered in Wetherby, West Yorkshire. The company went IPO on 2003-09-08. The firm is focused on developing cancer immunotherapies and diagnostics based on its Affimer and prelCISION platforms. The company has two divisions: Therapeutics and Diagnostics. Avacta’s therapeutics division develops cancer immunotherapies combining its platforms: Affimer biotherapeutics and prelCISION tumor targeted chemotherapy. The Affimer platform is a class of biotherapeutic based on a naturally occurring human protein. Avacta's prelCISION targeted chemotherapy platform releases active chemotherapy in the tumor, which limits the systemic exposure that causes damage to healthy tissues, and thereby improves the overall safety and therapeutic potential of these anti-cancer treatments. Avacta’s diagnostics division utilizes its Affimer platform to develop diagnostics and works with partners world-wide to develop Affimer reagents with the objective of establishing royalty-bearing license deals.

AVCT Intrinsic Value
55.94 GBX
Overvaluation 22%
Intrinsic Value
Price
Back to Top